Glaucoma Epidemiology Forecast

DelveInsight's 'Glaucoma - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Glaucoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Glaucoma Understanding

The DelveInsight Glaucoma epidemiology report gives a thorough understanding of the Glaucoma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Glaucoma in the US, Europe, and Japan. The report covers the detailed information of the Glaucoma epidemiology scenario in seven major countries (US, EU5, and Japan).


Glaucoma Epidemiology Perspective by DelveInsight

The Glaucoma epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Glaucoma epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Glaucoma epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Glaucoma Detailed Epidemiology Segmentation

The Glaucoma epidemiology covered in the report provides historical as well as forecasted Glaucoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Glaucoma report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Glaucoma report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Glaucoma Epidemiology Report and Model provide an overview of the risk factors and global trends of Glaucoma in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Glaucoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Glaucoma
  • The report provides the segmentation of the Glaucoma epidemiology


Report Highlights

  • 11-Year Forecast of Glaucoma epidemiology
  • 7MM Coverage
  • Total Cases of Glaucoma
  • Total Cases of Glaucoma according to segmentation
  • Diagnosed cases of Glaucoma


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Glaucoma?
  • What are the key findings pertaining to the Glaucoma epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Glaucoma across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Glaucoma?
  • What are the currently available treatments of Glaucoma?


Reasons to buy

  • The Glaucoma Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Glaucoma market
  • Quantify patient populations in the global Glaucoma market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Glaucoma therapeutics in each of the markets covered
  • Understand the magnitude of Glaucoma population by its epidemiology
  • The Glaucoma Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Glaucoma

3. Glaucoma: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Glaucoma Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Glaucoma Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Glaucoma Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Glaucoma Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Glaucoma Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Glaucoma Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Glaucoma Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Glaucoma Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Glaucoma Treatment and Management

6.2. Glaucoma Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Glaucoma Epidemiology in 7MM (2017-2030)

Table 2 Glaucoma Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Glaucoma Epidemiology in the United States (2017-2030)

Table 4 Glaucoma Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Glaucoma Epidemiology in Germany (2017-2030)

Table 6 Glaucoma Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Glaucoma Epidemiology in France (2017-2030)

Table 8 Glaucoma Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Glaucoma Epidemiology in Italy (2017-2030)

Table 10 Glaucoma Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Glaucoma Epidemiology in Spain (2017-2030)

Table 12 Glaucoma Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Glaucoma Epidemiology in the United Kingdom (2017-2030)

Table 14 Glaucoma Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Glaucoma Epidemiology in Japan (2017-2030)

Table 16 Glaucoma Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Glaucoma Epidemiology in 7MM (2017-2030)

Figure 2 Glaucoma Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Glaucoma Epidemiology in the United States (2017-2030)

Figure 4 Glaucoma Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Glaucoma Epidemiology in Germany (2017-2030)

Figure 6 Glaucoma Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Glaucoma Epidemiology in France (2017-2030)

Figure 8 Glaucoma Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Glaucoma Epidemiology in Italy (2017-2030)

Figure 10 Glaucoma Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Glaucoma Epidemiology in Spain (2017-2030)

Figure 12 Glaucoma Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Glaucoma Epidemiology in the United Kingdom (2017-2030)

Figure 14 Glaucoma Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Glaucoma Epidemiology in Japan (2017-2030)

Figure 16 Glaucoma Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report


  • Tags:
  • Glaucoma Epidemiology
  • Glaucoma
  • Glaucoma Pipeline
  • Glaucoma Companies
  • Glaucoma prevalent population
  • Glaucoma incident population
  • Glaucoma patients diagnosed
  • Glaucoma treatment algorithm

Forward to Friend

Need A Quote